On September 5, 2025, in San Diego, iBio, Inc. revealed its financial outcomes for the fiscal year closing on June 30, 2025. As a NASDAQ-listed company under the symbol IBIO, iBio specializes in developing precision antibody treatments guided by artificial intelligence (AI). The corporation also shared advancements in its operations and overall performance during this period.